INDOCO

Indoco Remedies Share Price

₹299.90 -4.4 (-1.45%)

21 Nov, 2024 14:18

SIP TrendupStart SIP in INDOCO

Start SIP

Performance

  • Low
  • ₹299
  • High
  • ₹305
  • 52 Week Low
  • ₹287
  • 52 Week High
  • ₹415
  • Open Price₹303
  • Previous Close₹304
  • Volume38,298

Investment Returns

  • Over 1 Month -12.17%
  • Over 3 Month -10.65%
  • Over 6 Month -6.75%
  • Over 1 Year -13.56%
SIP Lightning

Smart Investing Starts Here Start SIP with Indoco Remedies for Steady Growth!

Invest Now

Indoco Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 86.2
  • PEG Ratio
  • -1.2
  • Market Cap Cr
  • 2,765
  • P/B Ratio
  • 2.5
  • Average True Range
  • 8.81
  • EPS
  • 2.66
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -8.76
  • RSI
  • 34.52
  • MFI
  • 73.58

Indoco Remedies Financials

Indoco Remedies Technicals

EMA & SMA

Current Price
₹299.90
-4.4 (-1.45%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹314.10
  • 50 Day
  • ₹327.14
  • 100 Day
  • ₹333.75
  • 200 Day
  • ₹338.04

Resistance and Support

306 Pivot Speed
  • R3 314.60
  • R2 312.30
  • R1 308.30
  • S1 302.00
  • S2 299.70
  • S3 295.70

What's your outlook on Indoco Remedies?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Indoco Remedies Ltd. is a leading Indian pharmaceutical company specializing in the manufacturing and marketing of generic formulations, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company focuses on quality, innovation, and compliance across various therapeutic segments.

Indoco Remedies has an operating revenue of Rs. 1,773.21 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 7% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 32%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 23 which is a POOR score indicating inconsistency in earnings, a RS Rating of 24 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Indoco Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-24 Quarterly Results
2024-07-23 Quarterly Results
2024-05-16 Audited Results & Final Dividend
2024-01-23 Quarterly Results
2023-10-19 Quarterly Results

Indoco Remedies F&O

Indoco Remedies Shareholding Pattern

58.75%
16.74%
0.13%
1.7%
16.3%
6.38%

About Indoco Remedies

  • NSE Symbol
  • INDOCO
  • BSE Symbol
  • 532612
  • Managing Director
  • Ms. Aditi Panandikar
  • ISIN
  • INE873D01024

Similar Stocks to Indoco Remedies

Indoco Remedies FAQs

Indoco Remedies share price is ₹299 As on 21 November, 2024 | 14:04

The Market Cap of Indoco Remedies is ₹2764.5 Cr As on 21 November, 2024 | 14:04

The P/E ratio of Indoco Remedies is 86.2 As on 21 November, 2024 | 14:04

The PB ratio of Indoco Remedies is 2.5 As on 21 November, 2024 | 14:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23